Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;99(1):92-100.
doi: 10.1002/cpt.277. Epub 2015 Nov 23.

Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions

S Hennessy  1 , C E Leonard  1 , J J Gagne  2 , J H Flory  1   3   4 , X Han  1 , C M Brensinger  1 , W B Bilker  1
Affiliations
Review

Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions

S Hennessy et al. Clin Pharmacol Ther. 2016 Jan.

Abstract

A drug-drug interaction (DDI) occurs when one or more drugs affect the pharmacokinetics (the body's effect on the drug) and/or pharmacodynamics (the drug's effect on the body) of one or more other drugs. Pharmacoepidemiologic studies are the principal way of studying the health effects of potential DDIs. This article discusses aspects of pharmacoepidemiologic research designs that are particularly salient to the design and interpretation of pharmacoepidemiologic studies of DDIs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest / Disclosure

SH receives salary support through his employer for a study funded by AstraZeneca and Bristol-Myers Squibb, oversees a pharmacoepidemiology training program that receives support from Pfizer Inc and Sanofi, and in the past year has served as a consultant to Abbvie Inc, Merck Sharpe & Dohme Corp, Collegium Pharmaceutical Inc and a law firm representing Hoffman-LaRoche. JJG is a consultant to Aetion, Inc., a software company. WBB serves as a consultant to Johnson & Johnson. None of the other authors reports relevant relationships.

Figures

Figure 1
Figure 1
Schematic depiction the two different potential time-courses of a precipitant-triggered drug-drug interaction.
Figure 1
Figure 1
Schematic depiction the two different potential time-courses of a precipitant-triggered drug-drug interaction.
See this image and copyright information in PMC

References

    1. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003 Mar 5;289(9):1107–1116. - PubMed
    1. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007 Jun;16(6):641–651. - PubMed
    1. Harris Y, Hu DJ, Lee C, Mistry M, York A, Johnson TK. Advancing Medication Safety: Establishing a National Action Plan for Adverse Drug Event Prevention. Jt Comm J Qual Patient Saf. 2015;41(8):351–360. - PubMed
    1. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009 Feb;8(2):111–128. - PubMed
    1. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003 Nov;48(2):133–143. - PubMed

Publication types